We then examined the chemosensitizing effect of various EGFR-TKIs (afatinib, erlotinib, gefitinib, lapatinib, and pelitinib) in AML cell lines and investigated the association between LEPRE1 expression levels and sensitivity to EGFR-TKI treatment (Supplementary Fig. 2). This evidence concerns the gene EGFR and acute myeloid leukemia.